# ⏳ Final Week: Common Stock Bonus Ends Thursday | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/386902
- Entity ID: wefunder:feed_item:386902
- Published at: 2026-09-15 15:39:19 UTC
- Updated at: 2026-09-24 02:39:49 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen-Jam Investors & Community,This is the final week to receive bonus common shares with an investment in Sen‑Jam’s current financing round. The bonus opportunity closes Thursday, September 17. 🚨📍 Where We AreThis past year, Sen‑Jam reached two important milestones:🧪 We completed a rigorous human clinical study of our lead product—a patented combination of two of the world’s most trusted, long-approved medicines.🏛️ We met with the FDA to chart the path forward.The results strengthened our conviction. The study showed that our combination approach can provide relief across a broader range of symptoms than either medicine alone, with encouraging tolerability. It also revealed that the opportunity in front of us is bigger than a single product.The consumer medicine aisle has not seen true innovation in decades. Today’s products treat pain or allergies, but nothing addresses symptoms as people actually experience them—pain together with nausea, stomach upset, and inflammation—in a form that allows them to stay alert and get on with their day.💡 Our science points directly to that gap, and we are building our patent estate to protect it.🚀 Where We Are GoingSen‑Jam is now advancing a platform, not just a product.The same combination science powering our lead program is being directed at six of the most common conditions people face:🍸 Hangover🔒 Consumer Health Opportunity I — IP under review🔒 Consumer Health Opportunity II — IP under review🔒 Consumer Health Opportunity III — IP under review💪 Exercise-related muscle soreness🤧 The common coldEach represents a large, established market waiting for a modern solution.Because our components are already approved and trusted, we believe our development path can be faster, less costly, and lower-risk than traditional drug development. Every program shares the same scientific, manufacturing, and regulatory foundation—so each step forward can strengthen the entire portfolio. 🔗Our plan is deliberately disciplined: conduct small, decisive studies that answer the biggest questions before larger investments are made. 🎯Together, these markets represent more than $20 billion in annual U.S. consumer health spending.What began as one promising product has become a platform company with multiple paths to success—and we believe the coming year will show shareholders what that platform can do. 📈⏰ Final Opportunity for the Common Stock BonusIf you are an accredited investor and have been considering participating, this is the final week to invest with the common stock bonus.Your investment helps Sen‑Jam:🧬 Advance our clinical programs🗺️ Demonstrate Atlas through a scientifically reviewable proof of concept🌉 Build the bridge to our next major value-creating milestonesThank you for believing in Sen‑Jam and helping us build the next chapter.👉 Invest Here Let’s do this. 🚀JimAll investments involve risk, including the possible loss of capital. Bonus perks, if applicable, are subject to the terms of the offering and Wefunder materials. Please review the full offering materials on Wefunder before making any investment decision.